How Advocacy can Influence Pricing & Policy

Slides:

Advertisements

Similar presentations

The de-linkage of the cost of research and development and the price of health products Michelle Childs Director Policy Advocacy.

Advertisements

Differential pricing and access to medicines: issues and options Andrew Creese Essential Drugs and Medicines Policy Health Technology and Pharmaceuticals.

Prize for TB low-cost point of care rapid diagnostic test Pierre Chirac Médecins Sans Frontières, Paris, France Campaign for Access to Essential Medicines.

Actions Developing in Countries Accessing the WTO System Vung Tau, February 2006 “US – Brazil Compulsory licensing.

Patent Pools Increasing access to Medicines and Innovation Ellen ‘t Hoen MSF Access to Essential Medicines Campaign Barcelona 9 Dec

The Medicines Patent Pool advancing innovation, expanding access, promoting public health Charles Clift Chair, Medicines Patent Pool

XIX International AIDS Conference July 2012 Washington DC, USA The Brazilian experience: the campaign for access to lopinavir/ritonavir and efavirenz compulsory.

[INSERT SPEAKER’S NAME] [INSERT TITLE] [INSERT DATE]

Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.

Game Changers Radicalization of ART tools and delivery New ways to manage IP: aggressive use of TRIPS flex and effective patent pool Financial transaction.

Access to essential medicines of the future Bernard Pécoul Director, Campaign for Access to Essential Medicines Médecins Sans Frontières.

Access to Innovation: Making Generic Versions of Newer Antiretrovirals Affordable Focusing on middle income countries Leena Menghaney, MSF Access Camapign.

The UNITAID-funded MSF diagnostics project: Plans to incorporate the new WHO recommendations and how best practices will be shared with, and disseminated.

Intellectual Property and Access to Affordable Medicines: TRIPS Plus

1 Intellectual Property Rights in Medicines Procurement Patrick Osewe Senior HIV/AIDS Specialist World Bank.

A very short introduction to patents & access to medicines.

TRIPS flexibilities and examples which resulted in reduced medicine prices: Model legislation and compulsory licensing in Brazil Juliana V. Borges Vallini.

Antiretrovirals Pricing: The Past, The Present, The Future Janice Lee.

Access to Essential Medicines and Intellectual Property Rights in Developing Countries Rachel M. Cohen Access to Essential Medicines Campaign Doctors Without.

Physicians and Health Care Workers’ Role in Conflict Zones Challenges and Successes Babak Abbaszadeh March 27, 2010, Ottawa.

Washington D.C., USA, July 2012www.aids2012.org Intellectual Property-related challenges: A Latin America Perspective GraciaVioleta Ross

PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.

UNITAID The HIV/AIDS Medicines Patent Pool Initiative October 2010.

Data Exclusivity and Access to Medicines – Empirical Evidence Hearing European Parliament: EU-India Free Trade Agreement: What Future for Patients in Developing.

MSF Access Campaign Started in 1999 Rooted in field experience Three Pillars: –Overcoming Barriers –Research and Development for Drugs for Neglected Diseases.

Getting the best treatment to the most people possible Enabling policies: threats & opportunities MSF Access Campaign.

Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.

Lessons learned from the Global Fund’s Price and Quality Reporting (PQR) database T Patrick Aylward, Sophie Logez, Thuy Huong Ha, Monika Zweygarth, Carmen.

TRIPS TRIPS is the Agreement on Trade Related Aspects of Intellectual Property Rights Framed within the WTO, by “consensus” Regulates intellectual property.

PATENT POOL & its CONCERNS PATENT POOL & its CONCERNS Manmohan A Amonkar 20 July 2010.

Donors, prize funds and patent pools. KEI & UNU- MERIT Maastricht Workshop on Medical Innovation Prizes January 28th-29th 2008 Michelle Childs, Head of.

Ellen ‘t Hoen Médecins sans Frontières

Washington D.C., USA, July 2012www.aids2012.org Patent Oppositions in Argentina International AIDS Conference July 2012 M. Lorena Di Giano.

Tensions between Brazil and the United States

Access to Medicines Making Innovation work for the poor Corinna Heineke Diversity in Innovation European Patent Conference, Brussels, 15/16 May 2007.

"We are not sure that words can always save lives, but we know that silence can certainly kill." "Silence has long been confused with neutrality, and has.

Sources and prices of newer ARVs: Prospects for Pricing and Availability XVI International AIDS Conference Satellite Session -- August 13, 2006 Médecins.

Trade & Access to Medicines in India Centre for Trade & Development

Universal Access: To what extent current mechanisms are appropriate and sustainable to maintain free of charge treatment? Compulsory Licensing in Brazil.

Washington D.C., USA, July 2012www.aids2012.org An advocacy tool: Untangling the Web of Antiretroviral Price Reductions Arax Bozadjian HIV Focused.

Strategies to increase access to high priced medicines and vaccines: lessons, new challenges and opportunities Judit Rius Sanjuan U.S. Manager & Legal.

Access to medicines challenges in Europe: What is wrong and the way forward Presented by: Rohit Malpani Director of Policy & Analysis, Access Campaign.

NAFTA, CAFTA and Access to Medicines and Food Security in Latin America International Aids Conference Session “Globalization and FTAs: their impact, access.

Malebona Precious Matsoso Director General: Health 22 July 2016 AIDS 2016 CONFERENCE Essential Medicines, Intellectual Property and Access.

ANTI COUNTERFEIT FROM COMMUNITY PERSPECTIVE -Estimates indicates 30% of drugs in Kenyan market are fake. -40 billion lost every year due to counterfeit.

VOLUNTARY PATENT POOLING FOR PUBLIC HEALTH A Model For Innovation And Access.

iHEA 9th World Congress Sydney, July 8, 2013

MODERN AFRICA (21st Century)

MSF Access to Essential Medicines Campaign

How Pricing Affects Availability

Intellectual Property and Access to Affordable Medicines: TRIPS Plus

ACCESS TO QUALITY MEDICINES IN THE REGION-COUNTERFEITING PROBLEMS

WTO and medicines: from Doha to Cancún

Intellectual Property Protection and Access to Medicines

Trade Union Training on the Validation of the training manual entitled “Union Training on Occupational Safety and Health” HEALTH & HIV/AIDS.

Making medicines, diagnostics and other commodities more affordable

INTRODUCTION TO HIV IN EMERGENCIES

PATENTS, TRIPS, FLEXIBILITIES & ACCESS TO MEDICINES

Expanding ARV treatment in developing countries: Issues and Prospects

CARE-FINANCING-ACCESS

Managing Women Living With HIV Infection

MODERN (21st Century) Africa

Mechanisms to address IP related Barriers in Middle-Income Countries

From Balance sheet to economic analysis

Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies Introduction and Overview May 30 to June 4, 2005 Abuja, Nigeria.

A glimpse to the future: The ARV pipeline up to how do we ensure it is affordable and acceptable? Helen McDowell Head of Government Affairs & Global.

Treat the world: Working united across diseases for quality and affordable treatment for all – AIDS 2018 TRIPS Flexibilities 0.2 Across Diseases Ellen.

UF can do its part to close the access-to-medicines gap

Intellectual Property Rights in Medicines Procurement

Presentation transcript:

How Advocacy can Influence Pricing & Policy Jessica Burry HIV/HCV Pharmacist July 2017

MSF and Access to Medicines Médecins Sans Frontières (MSF), founded in 1971, is an international, independent, medical humanitarian organization that delivers emergency aid to people affected by armed conflict, epidemics, natural disasters and exclusion from healthcare in nearly 70 countries.

MSF and Access to Medicines Life saving essential medicines are either: Unaffordable Unavailable Unsuitable

What’s the Goal? Source: MSF Untangling the Web of Antiretroviral Price Reductions, 15th Edition, July 2012

Today: Still Unaffordable HIV: the price of a third-line regimen is more than 17 times higher than the recommended first-line Source: MSF Untangling the Web of antiretroviral Price Reductions, 18th Edition, July 2016

What are the Challenges? High price of ARVs? Intellectual Property (IP) barriers? Lack of suppliers in the market? Lack of generic competition? Small volumes in the market? Lack of transparancy : $ of R&D? $ of production?

What are the Challenges? High cost of Medicines? Intellectual Property (IP) barriers? Patent Analysis Patent Oppositions Dolutegravir

What are the Challenges? High cost of ARVs? Intellectual Property (IP) barriers? Patent Analysis Patent Oppositions Voluntary Licenses Compulsory Licenses E ‘t Hoen. Private Patents and Public Health: Changing intellectual property rules for access to medicines

What are the Challenges? High cost of ARVs?? Lack of suppliers in the market? Lack of generic competition? Small volumes in the market?

What are the Challenges? High cost of ARVs? Lack of transparancy $ of R&D? $ of production? $ of ARVs in other countries?

Tools & Communication

Communication

Communication

More Info! Waiting Isn’t An Option: HIV & Opportunistic Infection Treatment: Spotlight on Access Gaps: https://msfaccess.org/sites/default/files/HIV_Brief_SpotlightOnAccessGaps_ENG_2017.pdf Waiting Isn’t An Option: https://msfaccess.org/sites/default/files/HIVAIDS_Report_WaitingIsntAnOptionAdvancedHIV_ENG_2017_0.pdf

Merci! Thanks! @jessburry @MSF_Access www.msfaccess.org jessica.burry@geneva.msf.org